InMode Ltd. Reports First Quarter 2025 Financial Results

In a recent announcement, InMode Ltd., a leading global provider of innovative medical technologies, unveiled its financial results for the first quarter of 2025. The company, known for its pioneering radio-frequency technology platforms, reported a quarterly GAAP revenue of $77.9 million. This figure represents a 3% decrease compared to the $80.3 million reported in the same quarter of the previous year.

The slight dip in revenue comes amidst a challenging market environment, yet InMode remains steadfast in its commitment to innovation and global healthcare solutions. The company’s focus on developing cutting-edge medical devices continues to serve a diverse customer base worldwide.

In a strategic move, InMode completed a share repurchase program in April 2025, acquiring 6.95 million shares. This initiative reflects the company’s confidence in its long-term value and its dedication to enhancing shareholder value.

Analysts had mixed expectations leading up to the earnings announcement. On average, seven analysts anticipated an earnings per share (EPS) of $0.354, marking an improvement from the $0.280 EPS reported a year earlier. However, revenue projections were more conservative, with six analysts predicting a 3.43% decrease to $77.5 million, closely aligning with the actual results.

Despite the revenue decline, InMode’s non-GAAP EPS of $0.31 slightly missed expectations by $0.04. However, the company managed to exceed revenue forecasts by $0.31 million, showcasing resilience in its operational performance.

As InMode navigates the complexities of the healthcare sector, its strategic initiatives and commitment to innovation position it well for future growth. Investors and stakeholders will be keenly watching the company’s next steps as it continues to expand its global footprint and enhance its product offerings.

InMode’s stock, listed on the Nasdaq under the ticker INMD, reflects the dynamic nature of the healthcare sector, with a market capitalization of $1.09 billion. The company’s price-to-earnings ratio stands at 6.9, indicating a balanced valuation in light of its recent performance.

For more detailed insights and updates, stakeholders are encouraged to visit InMode’s official website at www.inmodemd.com . As the company progresses, its innovative approach to healthcare solutions remains a cornerstone of its strategy, promising continued advancements in medical technology.